Data Insights

Talimogene laherparepvec by Amgen for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Human Epidermal Growth Factor Receptor 2...

Data Insights

Talimogene laherparepvec by Amgen for Kaposi Sarcoma: Likelihood of Approval

Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Kaposi Sarcoma. According to GlobalData, Phase...

Data Insights

Talimogene laherparepvec by Amgen for Metastatic Renal Cell Carcinoma: Likelihood of Approval

Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Metastatic Renal Cell Carcinoma. According to...

Data Insights

Talimogene laherparepvec by Amgen for Metastatic Colorectal Cancer: Likelihood of Approval

Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...

Data Insights

Talimogene laherparepvec by Amgen for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...

Data Insights

Talimogene laherparepvec by Amgen for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to...

Data Insights

Talimogene laherparepvec by Amgen for Non-Small Cell Lung Cancer: Likelihood of Approval

Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Non-Small Cell Lung Cancer. According to...

Data Insights

Talimogene laherparepvec by Amgen for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...

Data Insights

Talimogene laherparepvec by Amgen for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - Talimogene Laherparepvec in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

Talimogene laherparepvec by Amgen for Kaposi Sarcoma: Likelihood of Approval

Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Kaposi Sarcoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Talimogene Laherparepvec in Kaposi Sarcoma

Data Insights

Talimogene laherparepvec by Amgen for Metastatic Renal Cell Carcinoma: Likelihood of Approval

Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Metastatic Renal Cell Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Talimogene Laherparepvec in Metastatic Renal Cell Carcinoma

Data Insights

Talimogene laherparepvec by Amgen for Metastatic Colorectal Cancer: Likelihood of Approval

Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Talimogene Laherparepvec in Metastatic Colorectal Cancer

Data Insights

Talimogene laherparepvec by Amgen for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Talimogene Laherparepvec in Gastroesophageal (GE) Junction Carcinomas

Data Insights

Talimogene laherparepvec by Amgen for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Talimogene Laherparepvec in Metastatic Hepatocellular Carcinoma (HCC)

Data Insights

Talimogene laherparepvec by Amgen for Non-Small Cell Lung Cancer: Likelihood of Approval

Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Talimogene Laherparepvec in Non-Small Cell Lung Cancer

Data Insights

Talimogene laherparepvec by Amgen for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Talimogene Laherparepvec in Triple-Negative Breast Cancer (TNBC)